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Abstract
Background: Histone deacetylase inhibitors (HDACIs) have many effects on cancer cells, such as
growth inhibition, induction of cell death, differentiation, and anti-angiogenesis, all with a wide
therapeutic index. However, clinical trials demonstrate that HDACIs are more likely to be effective
when used in combination with other anticancer agents. Moreover, the molecular basis for the anti-
cancer action of HDACIs is still unknown. In this study, we compared different combinations of
HDACIs and anti-cancer agents with anti-angiogenic effects, and analysed their mechanism of
action.
Results: Trichostatin A (TSA) and α-interferon (IFNα) were the most effective combination
across a range of different cancer cell lines, while normal non-malignant cells did not respond in the
same manner to the combination therapy. There was a close correlation between absence of basal
p21WAF1 expression and response to TSA and IFNα treatment. Moreover, inhibition of p21WAF1
expression in a p21WAF1-expressing breast cancer cell line by a specific siRNA increased the
cytotoxic effects of TSA and IFNα. In vitro assays of endothelial cell function showed that TSA and
IFNα decreased endothelial cell migration, invasion, and capillary tubule formation, without
affecting endothelial cell viability. TSA and IFNα co-operatively inhibited gene expression of some
pro-angiogenic factors: vascular endothelial growth factor, hypoxia-inducible factor 1α and matrix
metalloproteinase 9, in neuroblastoma cells under hypoxic conditions. Combination TSA and IFNα
therapy markedly reduced tumour angiogenesis in neuroblastoma-bearing transgenic mice.
Conclusion:  Our results indicate that combination TSA and IFNα therapy has potent co-
operative cytotoxic and anti-angiogenic activity. High basal p21WAF1 expression appears to be acting
as a resistance factor to the combination therapy.
Background
Acetylation and deacetylation of histones by histone
acetyltransferases and histone deacetylases (HDACs) alter
chromatin structure and modulate transcriptional regula-
tion (reviewed in [1-3]. Inhibitors of HDACs (HDACIs)
are emerging as a new class of anticancer agents. HDACIs
Published: 25 October 2007
Molecular Cancer 2007, 6:68 doi:10.1186/1476-4598-6-68
Received: 25 July 2007
Accepted: 25 October 2007
This article is available from: http://www.molecular-cancer.com/content/6/1/68
© 2007 Kuljaca et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2007, 6:68 http://www.molecular-cancer.com/content/6/1/68
Page 2 of 11
(page number not for citation purposes)
induce cancer cell differentiation, growth arrest, pro-
grammed cell death, and inhibit tumour-driven angiogen-
esis [1,3]. Clinical trials with HDACIs in cancer patients
demonstrate that HDACI treatment leads to tumour
regression and symptomatic improvement in some heav-
ily pre-treated and multiply relapsed patients, with a sur-
prisingly low side-effect profile [1,4]. However, a large
proportion of the patients are not sensitive to the treat-
ment, demonstrating the need to examine the effective-
ness of HDACIs in combination with other anti-cancer
agents.
Angiogenesis is vital for tumor progression and metastasis
[5,6]. As anti-angiogenic therapy is generally less toxic and
better tolerated than conventional cytotoxic chemother-
apy, strategies which combine anti-angiogenic agents with
other anti-cancer drugs have been the focus of current
clinical trials to widen the therapeutic index. The interfer-
ons (IFNs) are a family of naturally occurring cytokines
with anti-proliferative and anti-angiogenic effects [7,8].
Through inhibiting pro-angiogenic gene expression and
acting directly on endothelial cells, α-interferon (IFNα)
suppresses angiogenesis and tumour growth in vitro and in
vivo  [7,9]. Rapamycin and its derivatives also inhibit
tumour cell proliferation and angiogenesis by acting on
the mammalian target of rapamycin and suppressing the
transcriptional activity of pro-angiogenic hypoxia-induci-
ble factor 1α (HIF1α), (reviewed in [10]). While clinical
trials with IFNα, rapamycin and its derivatives used as sin-
gle agents have shown some effects, none of the drugs are
effective alone in the majority of patients.
It has been reported that a combination therapy with the
HDACI, valproate (VPA), and IFNα exerts synergistic anti-
cancer effects in neuroblastoma BE(2)-C cells both in vitro
and  in vivo [11,12]. Here we evaluated the anticancer
actions of combination therapy with HDACIs (Trichosta-
tin A [TSA] or VPA) and anti-cancer agents with anti-ang-
iogenic function (IFNα, rapamycin), and, sought to
determine their mechanism of action.
Results
TSA and IFNα exerted co-operative cytotoxic effects in 
cancer cell lines from a range of different tissue origins
The combination of the HDACI, VPA, and IFNα demon-
strated synergistic combinational anti-cancer effects in
neuroblastoma BE(2)-C cells both in vitro and  in vivo
[11,12]. We investigated the synergistic anti-cancer effect
of IFNα combined with other HDACIs, and, in cancer cell
lines of other tissue origins. We treated breast, lung, colon
and prostate cancer cells and MRC-5 normal non-malig-
nant fibroblasts with control, 0.02 μM TSA and/or 500
IU/ml IFNα, and, then assessed for cell viability. As shown
in Figure 1A, all of the cancer cell lines tested were sensi-
tive to the cytotoxic effects of the combination, and there
was a significant cooperative effect of TSA and IFNα in
eight of the nine cell lines tested, with MDA-MB-468 as
the only exception. MCF-7, Calu-6, H460, LNCaP, DU-
145, HT-29, Caco-2 and BE(2)-C cells were all sensitive to
TSA, generally less sensitive to IFNα, and significantly
more sensitive to TSA and IFNα combined. MDA-MB-468
breast cancer cells were sensitive to IFNα but resistant to
TSA, and no more sensitive to the combination than IFNα
alone. When cell sensitivity to the combination treatment
was calculated as a percentage of TSA alone (or IFNα
alone in case of MDA-MB-468), BE(2)-C, HT-29 and
Calu-6 were found to be the most sensitive (Figure 1A).
Importantly, the normal non-malignant MRC-5 fibrob-
lasts were resistant to the treatment of TSA alone, IFNα
alone and TSA plus IFNα combination therapy (Figure
1B). Immunoblot analysis of acetylated histone H3
revealed that treatment with TSA alone or TSA plus IFNα
for 6 hours induced drastic histone acetylation in the
MRC-5 cells (Figure 1B).
SAHA and IFNα exerted co-operative cytotoxic effects in 
cancer cell lines, but not in normal cells
The HDACI, SAHA (vorinostat), is in clinical use for the
treatment of cutaneous T-cell lymphoma. We, therefore,
tested whether a combination of SAHA and INFα exerted
co-operative anti-cancer effects. Neuroblastoma BE(2)-C,
breast cancer MCF-7, and normal lung fibroblast MRC-5
cells were treated with control, 0.5 μM SAHA, 500 IU/ml
INFα or SAHA plus INFα for 3 days. Alamar blue assays
revealed that SAHA and INFα co-operatively reduced the
viability of BE(2)-C and MCF-7 cells, although the magni-
tude was smaller than TSA and INFα. A combination of
SAHA and INFα did not co-operatively reduce the viabil-
ity of MRC-5 cells (Figure 2).
The effects of other HDACIs and anti-cancer agents used 
in combination
We compared the cytotoxicity of the TSA and IFNα com-
bination (Figure 1A) with combinations of another
HDACI VPA and IFNα (Figure 3A). The effect of VPA and
IFNα combination therapy on cell viability was similar to
TSA and IFNα for the BE(2)-C neuroblastoma cells. How-
ever, TSA and IFNα were more effective in MCF-7 and
Calu-6 cells than VPA and IFNα. Similar to TSA and IFNα,
VPA and IFNα did not show any co-operative cytotoxic
effects on normal MRC-5 fibroblasts (Figure 3C). We next
compared the cytoxicity of the TSA and IFNα combina-
tion (Figure 1A), the VPA and IFNα combination (Figure
3A) with VPA combined with another emerging antican-
cer agent with both cytotoxic and anti-angiogenic actions,
rapamycin [10] in BE(2)-C and MCF-7 cells (Figure 3B).
The VPA and rapamycin treatment had significant cyto-
toxic effects compared with VPA alone, but the magnitude
of these effects was much smaller than VPA and IFNα or
TSA and IFNα.Molecular Cancer 2007, 6:68 http://www.molecular-cancer.com/content/6/1/68
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TSA and IFNα exerted co-operative cytotoxic effects in cancer cell lines from a range of different tissue origins, but not in nor- mal non-malignant cells Figure 1
TSA and IFNα exerted co-operative cytotoxic effects in cancer cell lines from a range of different tissue origins, but not in nor-
mal non-malignant cells. A. Neuroblastoma [BE(2)-C], breast (MCF-7 and MDA-MB-468), lung (H460 and Calu-6), prostate 
(DU-145 and LNCaP), and colon (HT-29 and Caco-2) cancer cells were treated with control (Cont), 0.02 μM TSA and/or 500 
IU/ml IFNα for 72 hours. Cell viability was examined using the Alamar blue assay, measured as optical density (OD) units of 
absorbance, and expressed as the absorbance of treated over control samples (ie., % viable cells). ** p < 0.01, *** p < 0.001. B. 
MRC-5 cells were treated with control, 0.02 μM TSA and/or 500 IU/ml IFNα for 72 hours, and cell viability was assessed as 
above. Moreover, histone protein was extracted and subject to immunoblot analysis with anti-acetylated histone H3 antibody, 
after 6 hour exposure to control, TSA and/or IFNα.
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Absence of p21WAF1 expression correlated with sensitivity 
to TSA and IFNα combination therapy
Up-regulation of p21WAF1  expression, and p21WAF1-
induced cell cycle arrest, have been regarded as one of the
main mechanisms through which HDACIs exert their
anti-cancer effects[13]. We examined the role of p21WAF1
in cancer cell sensitivity to the combination therapy.
Immunoblot analysis of p21WAF1 expression was carried
out with protein extracted from the eight cell lines of
breast, lung, prostate and colon origins (Figure 4A).
p21WAF1 was basally expressed in untreated H460, DU-
145, LNCaP, MCF-7 and MDA-MB-468 cells, but not
expressed in Calu-6, HT-29 and Caco-2 cells. Compared
with control, TSA induced p21WAF1 expression in H460,
MCF-7 and LNCaP cells. IFNα up-regulated p21WAF1 only
in DU-145 cells, and, combination therapy increased
p21WAF1  in all four cell lines. p21WAF1  protein was
expressed but not altered by treatment with TSA and/or
IFNα in MDA-MB-468 cells. Thus, the cancer cell lines
which did not have basal expression of p21WAF1 were gen-
erally more sensitive to the combination therapy than
those cancer cells expressing p21WAF1. This correlation
suggested expression of p21WAF1 might render cancer cells
insensitive to the combination therapy.
To determine the role of p21WAF1 expression in cancer cell
sensitivity to TSA and IFNα combination therapy, MCF-7
cells were transfected with control, scrambled siRNA or
siRNA specifically targeting p21WAF1, and, then treated
with control, TSA and/or IFNα. RT-PCR and immunoblot
analysis revealed that p21WAF1 mRNA and protein were
knocked down by approximately 75% by the p21WAF1
siRNA, compared with scrambled control (Figure 4B). The
p21WAF1 siRNA significantly increased the sensitivity of
MCF-7 cells to TSA and IFNα alone, and, in combination,
as measured by cell viability assays (p < 0.01) (Figure 4C).
HDACI and IFNα co-operatively inhibit endothelial cell 
functions and pro-angiogenic gene expression in cancer 
cells in vitro
Since HDACIs [2,14] and IFNα [8,9] are known to sup-
press angiogenesis and tumour growth by acting directly
on endothelial cells, we further investigated whether the
combination of TSA and IFNα could inhibit endothelial
cell function. To exclude the possibility that co-operative
anti-angiogenic effects by TSA and IFNα were due to cyto-
toxicity, we first determined the optimal dosages of TSA
and IFNα with Alamar blue cell viability assays. After
treatment for 18 hours under normoxic or hypoxic condi-
tions (1% O2), a combination of 0.1 μM TSA and 500 IU/
ml IFNα was found to have no cytotoxicity on endothelial
cells within 18 hours after treatment (Figure 5A). These
doses were, therefore, used in all endothelial cell function
studies. Surprisingly, TSA or IFNα alone stimulated
endothelial cell migration toward the chemoattractant,
vascular endothelial growth factor (VEGF) (Figure 5B). In
contrast, the combination of TSA and IFNα suppressed
endothelial cell migration under both hypoxic (Figure 5B)
or normoxic conditions (data not shown). Compared
with control, IFNα or TSA alone reduced endothelial cell
invasion through Matrigel by 35% and 60%, respectively,
whereas the combination of TSA and IFNα decreased cell
invasion by 80%, under normoxic (data not shown) or
hypoxic conditions (Figure 5C). Under normoxic condi-
tions, compared with control, IFNα or TSA alone
decreased the number of complete branches per branch-
ing point by 30% and 50%, respectively, while TSA and
IFNα did not further decrease complete branches per
branching point (data not shown). In contrast, under
hypoxic conditions, the combination of TSA and IFNα
decreased complete branches per branching point by
50%, while TSA or IFNα alone reduced the average num-
bers of complete branches from a branching point by only
25% (Figure 5D).
We next evaluated whether the combination of TSA
[15,16] and IFNα [7,17] represses pro-angiogenic gene
expression, as measured by RT-PCR, in neuroblastoma
BE(2)-C cells. Compared with treatment with TSA or IFNα
alone, the combination therapy significantly down-regu-
lated gene expression of HIF1α, VEGF and MMP-9 under
normoxic conditions at 72 hours after treatment, while no
co-operative effects were observed on the expression of
MMP-2, activin A, thrombospondin-1, von Hippel-
Lindau protein and bFGF (data not shown). Suppression
of HIF1α, VEGF and MMP-9 gene expression by TSA and
IFNα was more significant, when compared with TSA or
IFNα alone, under hypoxic conditions (Figure 5E). In the
case of HIF1α and VEGF, IFNα alone repressed gene
SAHA and IFNα exerted co-operative cytotoxic effects in  cancer cell lines, but not in normal non-malignant cells Figure 2
SAHA and IFNα exerted co-operative cytotoxic effects in 
cancer cell lines, but not in normal non-malignant cells. Neu-
roblastoma BE(2)-C, breast cancer MCF-7, and normal non-
malignant lung MRC-5 fibroblasts were treated with control, 
0.5 μM SAHA and/or 500 IU/ml IFNα for 72 hours. Cell via-
bility was examined using the Alamar blue assay, measured as 
optical density (OD) units of absorbance, and expressed as 
the absorbance of treated over control samples (ie., % viable 
cells). * p < 0.05, ** p < 0.01, *** p < 0.001.
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expression, however, the combination still had a more
significant repressive effect, compared with IFNα alone (p
< 0.05). Although MMP-9 gene expression was stimulated
by IFNα and TSA alone, the combination suppressed its
expression, when compared with control-treated samples
(p < 0.05).
TSA and IFNα co-operatively suppress tumour-driven 
angiogenesis in neuroblastoma-bearingN-Myc transgenic 
mice
Lastly, we tested whether the combination of TSA and
IFNα could co-operatively inhibit tumor-driven angio-
genesis in vivo. Abdominal neuroblastoma first became
palpable in 100% of homozygote N-Myc transgenic mice
at 4 weeks of age [18]. Cohorts of five homozygous MYCN
The cytotoxic effects of other HDACI combination therapies Figure 3
The cytotoxic effects of other HDACI combination therapies. A. Neuroblastoma [BE(2)-C], breast (MCF-7), and lung (Calu-6) 
cancer cell lines were treated with either control, 500 IU/ml IFNα and/or various dosages of VPA for 72 hours B. In separate 
experiments, BE(2)-C and MCF-7 cells were treated with control, 1 mM VPA and/or various dosages of rapamycin (RAP) for 
72 hours. C. Non-malignant lung fibroblast (MRC-5) cells were treated with a range of VPA doses alone, or in combination 
with 500 IU/ml IFNα. Cell viability was examined by the Alamar blue assay, measured as optical density (OD) units of absorb-
ance, and expressed as a percentage of absorbance for treated samples, over that for control samples (ie., % viable cells). ** p 
< 0.01, *** p < 0.001.
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Absence of p21WAF1 expression correlated with sensitivity to TSA and IFNα combination therapy Figure 4
Absence of p21WAF1 expression correlated with sensitivity to TSA and IFNα combination therapy. A. MCF-7, MDA-MB-468, 
H460, Calu-6, DU-145, LNCaP, HT-29 and Caco-2 cells were treated with control, 0.02 μM TSA, 500 IU/ml IFNα, or TSA and 
IFNα for 24 hours. Whole cell protein was extracted and subjected to immunoblot with an anti- p21WAF1 antibody, and, an 
anti-actin antibody as a loading control. B. MCF-7 cells were transfected with control scrambled or p21WAF1 siRNA for 8 hours, 
followed by treatment with control, 0.02 μM TSA and/or 500 IU/ml IFNα for 72 hours. The effect of the siRNAs on p21WAF1 
gene and protein expression was analysed by semi-quantitative RT-PCR with the house-keeping gene β-2-microglobulin (β2M) 
as a loading control or by immunoblot, with actin as a loading control. C. Cell viability was examined by the Alamar blue assay, 
measured as optical density (OD) units of absorbance, and expressed as percentage of absorbance for drug-treated samples 
over control-treated samples (% viable cells). ** p < 0.01.
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HDACI and IFNα co-operatively inhibit endothelial cell functions, and pro-angiogenic gene expression in cancer cells under  hypoxic conditions in vitro Figure 5
HDACI and IFNα co-operatively inhibit endothelial cell functions, and pro-angiogenic gene expression in cancer cells under 
hypoxic conditions in vitro. A. Human umbilical vein endothelial cells (HUVECs) were treated with control (Cont), 0.1 μM TSA 
and/or 500 IU/ml IFNα for 18 hours. Cell viability was evaluated with the Alamar blue assay. B. HUVECs were plated in BD 
Biosciences Fluroblok chambers and treated with control, 0.1 μM TSA and/or 500 IU/ml IFNα for 22 hours. Cells were stained 
with Cell Tracker Green CMFDA, migrated through chamber filters toward the chemo-attractant VEGF, and then quantified 
and expressed as optical density (OD) absorbance units. C. HUVECs were plated into BD BioCoat growth factor-reduced 
matrigel invasion chambers and treated with control, 0.1 μM TSA and/or 500 IU/ml IFNα for 18 hours. Cells which invaded 
through the Matrigel were fixed, stained with a Diff Quick staining kit, photographed and then quantified. D. HUVECs were 
plated onto growth factor-reduced Matrigel in 24 well plates and treated with control, 0.1 μM TSA and/or 500 IU/ml IFNα for 
18 hours. Vascular sprouting was quantified by counting the numbers of complete branches per branching point. E. Neuroblas-
toma BE(2)-C cells were treated with control, 0.02 μM TSA and/or 500 IU/ml IFNα for 72 hours under hypoxic (1% O2) con-
ditions. RNA was extracted and subjected to independent semi-competitive RT-PCR analyses using trans-intron PCR primers, 
together with primers for the house-keeping gene β-2 microglobulin (β2M). Representative gels for each gene at the 72 hour 
time point were shown, and fold induction of a target gene by treatment was calculated by ascribing the ratio between the level 
of expression of a target gene and that of β2M as 1.0 for control treated samples. * p < 0.05, ** p < 0.01, *** p < 0.001.
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transgenic mice at four weeks of age, were treated with
control, IFNα, TSA, or TSA and IFNα for one week after
abdominal tumors were first palpable. After mice were
sacrificed, tumour volume was measured, and microvas-
culature assessed by immunohistochemical staining for
platelet endothelial cell adhesion molecule 1 (PECAM-1)
expression (Figure 6). When tumour volume was ana-
lysed, TSA alone suppressed tumour progression by 87%,
while IFNα alone reduced tumour volume by about 36%,
compared with control treated mice. The combination of
TSA and IFNα reduced tumour volume by more than
92%, although this was not statistically significant com-
pared with TSA treatment alone. When tumour micro-vas-
culature was assessed by PECAM-1 staining, the use of TSA
or IFNα alone, decreased micro-vasculature formation by
32% and 53%, respectively. However, the combination of
TSA and IFNα exerted co-operative anti-angiogenic
effects, reducing micro-vasculature by almost 90% (Figure
6)
Discussion
HDACIs have shown great promise in clinical trials in can-
cer patients. However, a majority of patients have been
insensitive to the treatment. In this study, we found that
the combination of IFNα with the HDACI TSA induced
co-operative cytotoxic effects in almost all cancer cell lines
of diverse tissue types, and demonstrated little cytoxicity
in normal non-malignant cells. The combination of IFNα
with the HDACI SAHA, already in clinical use, also exerted
co-operative anti-cancer effects, with little effect on nor-
mal cells. The combination of IFNα with another HDACI,
VPA, was less effective than IFNα and TSA, but more effec-
tive than VPA and rapamycin. These results suggest that
HDACI and IFNα combination therapy may be an effec-
tive anti-cancer strategy for future clinical trials.
Our data identified p21WAF1 expression as a key factor
responsible for cancer cell resistance to the cytotoxic
effects of combination HDACI and IFNα therapy. While
IFNα can both induce or suppress p21WAF1 gene transcrip-
tion in different cells [19], it is the most common tran-
scriptional target of HDACIs (reviewed in [2]). Previous
literature suggested that up-regulation of p21WAF1  by
HDACIs may mediate HDACI-induced cell cycle arrest
and growth inhibition [13]. However, recent publications
have cast doubt on the role of p21WAF1 in the action of
HDACIs, and, conversely demonstrated that inducible
p21WAF1 reduced HDACI-induced cell death [20-24]. Our
TSA and IFNα co-operatively suppress tumour-driven angiogenesis in neuroblastoma bearing transgenic MYCN mice Figure 6
TSA and IFNα co-operatively suppress tumour-driven angiogenesis in neuroblastoma bearing transgenic MYCN mice. A. Phot-
omicrographs of neuroblastoma tumour tissue sections from homozygous MYCN transgenic mice treated with either control, 
TSA, IFNα, or TSA and IFNα, which were subject to immunohistochemical studies using an anti-PECAM-1 antibody. Arrows 
indicate PECAM-1 positive microvessels (brown colored). B. Quantitation of the number of PECAM positive microvessels per 
40× high power field in neuroblastoma tumour cross-sections. *** p < 0.001.
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data suggests p21WAF1 expression in some cancer cells acts
as a resistance factor for the cytotoxic effects of TSA and
IFNα combination therapy.
The individual effects of HDACIs and IFNα on angiogen-
esis predict a co-operative therapeutic role in blocking
tumour angiogenesis. Expression of HDACs is often up-
regulated under angiogenic stimuli such as hypoxia in
cancer cells, and HDACIs can suppress HIF1α expression
and its down-stream targets, including VEGF[25]. HDA-
CIs have been recently demonstrated to inhibit endothe-
lial cell migration, invasion, vascular sprouting in vitro,
and vasculature formation in animal models of cancer
[14,16,26]. IFNα can repress VEGF and MMP-9 gene
expression, endothelial cell functions, and, inhibit
tumour-driven angiogenesis in vivo [9,27]. In our
endothelial cell migration experiments, we found in con-
trast, that either TSA or IFNα alone stimulated migration.
We cannot fully explain the discrepancy between our data
and previously published migration assays [14], however,
this may be due to different characteristics of the migra-
tion chamber used. Importantly, the combination of
HDACI and IFNα suppressed all endothelial cell func-
tions, indicating a possible role for this drug combination
as a therapy for cancer patients at the point of minimal
residual disease.
Conclusion
In summary, we have found that the combination of
HDACIs, TSA, SAHA and VPA, with IFNα have significant
cytotoxic effects on a wide variety of cancer cells, with lit-
tle toxicity to normal non-malignant cells. Inhibition of
p21WAF1 expression sensitizes p21WAF1-expressing cancer
cells to the combination therapy. Furthermore, HDACI
and IFNα co-operatively suppress pro-angiogenic gene
expression in cancer cells, multiple endothelial cell func-
tions in vitro, and tumour-driven vasculature formation in
vivo. Our results provide a basis for further in vivo studies
and eventual clinical trials using the combination of
HDACIs and IFNα.
Methods
Cell culture and reagentsThe neuroblastoma cell line,
BE(2)-C, was generously supplied by Dr J Biedler (Memo-
rial Sloan-Kettering Cancer Center, NY, USA). Breast
(MCF-7 and MDA-MB-468), lung (Calu-6 and H460),
prostate (DU-145 and LNCaP), and, colon (HT-29 and
Caco-2) cancer cells were purchased from American Type
Culture Collection (Manassas, VA, USA). All cell lines
were cultured in Dulbecco's modified Eagle's medium
supplemented with 10% fetal calf serum, with the excep-
tion of H460 and LNCaP, which were cultured in Roswell
Park Memorial Institute Medium, supplemented with
10% fetal calf serum. All cell lines were maintained in a
humidified incubator at 37°C and 5% CO2  in air.
TSA (Sigma, St. Luis, MO, USA) was dissolved in ethanol,
and SAHA (BioVision, Mountain View, CA) in dimethyl-
sulfoxide (Sigma). IFNα (Sigma) was diluted in serum
free cell culture medium and aliquoted as a stock solution
of 100 000 units/ml. For studies in animals, TSA was dis-
solved in dimethyl sulfoxide (Sigma) and further diluted
with saline solution to give the final concentration of 30%
dimethyl sulfoxide and 1 mg/ml TSA.
Endothelial cell culture
Human umbilical vein endothelial cells (HUVECs) were a
gift from Dr K MacKenzie (Children's Cancer Institute
Australia, Sydney, Australia). HUVECs were maintained
in 0.1% gelatin coated tissue culture flasks or wells with
medium 199 (Invitrogen, Carlsbad, CA, USA) supple-
mented with 20% fetal bovine serum, 5% human serum
(Sigma), 10 U/ml heparin (Pharmacia & Upjohn, Pea-
pack, NJ, USA), 5 ng/ml basic fibroblast growth factor
(bFGF) (Sigma) and 20 ug/ml endothelial growth factor
(Roche, Mannheim, Germany). Only passages 5 and 6
were used in the experiments. Hypoxic conditions were
maintained in a chamber filled with 1% oxygen.
Alamar blue cell viability assay
After plating in 96 well plates, cells were allowed to attach
for 24 hours, followed by treatment with various drugs for
72 hours. Before the end of treatment, cells were incu-
bated with Alamar blue (Invitrogen) for 5 hours, and
plates were then read on a micro-plate reader at 570/595
nm. Relative cell viability was calculated according to the
readings and expressed as optical density (OD) absorb-
ance units.
Immunoblot analysis
Twenty four hours after treatment with control, TSA and/
or IFNα, protein was extracted from whole cells, separated
by electrophoresis, and transferred onto nitrocellulose
membrane. Membranes were incubated with mouse anti-
human p21WAF1 antibodies (Santa Cruz Biotechnologies,
Santa Cruz, CA, USA) (1:1000), followed by goat anti-
mouse antibody (1:2000) conjugated with horseradish
peroxidase. Chemiluminescent detection was performed
using SuperSignal reagents (Pierce). Membranes were
then re-probed with an anti-β-actin antibody (Pierce), as
a loading control.
siRNA transfectionMCF7 cells were transfected with a val-
idated scrambled siRNA or siRNA specifically targeting
p21WAF1  (SmartPool siRNA CDKN1A, Dharmacon
Research, Lafayete, CO) with Lipofectamine 2000 trans-
fection reagent (Invitrogen) according to the manufac-
turer's recommendation. Cells were lysed, and RNA or
protein extracted 24 hours later for Reverse Transcription-
polymerase Chain Reaction (RT-PCR) or immunoblot
analysis of siRNA transfection efficacy.Molecular Cancer 2007, 6:68 http://www.molecular-cancer.com/content/6/1/68
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Semi-quantitative competitive RT-PCR
Semi-quantitative competitive RT-PCR was carried out as
described previously [28] to analyse siRNA transfection
efficiency in MCF-7 cells and the effect of TSA and/or
IFNα treatment on angiogenic gene expression in BE(2)-C
cells. Specific primers used for PCR were as follows: 5'-
CAGCAGAGGAAGACCATGTG-3' and 5'-GGCGTTTGGA
GTGGTAGAAA-3' for p21WAF1; 5'-TTACAGCAGCCAGAC-
GATCA-3' and 5'-ATTGCCCCAGCAGTCTACAT-3' for
HIF1α; 5'-CCTTGCTGCTCTACCTCCAC-3' and 5'-ATGA
TTCTGCCCTCCTCCTT-3' for vascular endothelial growth
factor (VEGF); 5'-TTCCCTGGAGACCTGAGAAC-3' and
5'-AGGGACAGTTGCTTCTGGAG-3' for metalloprotein-
ase-9 (MMP-9); 5'-ACCCCCACTGAAAAAGATGA-3' and
5'-ATCTTCAAACCTCCATGATG-3' for β2-microglobulin
(β2M).
Endothelial cell migration assay
HUVEC migration towards the chemo-attractant, VEGF
(Sigma), was tested using a BD Biosciences Fluroblok
(Becton Dickinson) endothelial cell migration system
according to the manufacture's guidelines. Cells were
labeled with 1 μM Cell Tracker Green CMFDA fluores-
cence solution (Invitrogen) for 30 minutes, and migrated
through filters into 24 well plates. Thereafter the plate was
read with a Fluroscence plate reader at 492/517 nm. The
relative cell number was calculated according to the read-
ings and expressed as optical density (OD) absorbance
units.
Endothelial cell invasion assay
HUVEC invasion through matrigel towards the chemo-
attractant, VEGF, was investigated using BD BioCoat,
growth factor-reduced Matrigel, endothelial cell invasion
chambers (Becton Dickinson), according to the manufac-
turer's guidelines. Endothelial cells which invaded
through the matrigel to the other side of the inserts, were
fixed and stained with Diff Quick staining kit (Baxter) and
photographed. The number of cells per 20× objective field
was counted under an inverted microscope.
Vascular sprouting (capillary tubule formation) assay
The vascular sprouting assays were performed on 24 well
plates coated with 250 μl of polymerized, growth factor-
reduced Matrigel matrix (Becton Dickinson) per well.
HUVECs were plated on Matrigel and treated with con-
trol, TSA and/or IFNα for 18 hours. Quantification of vas-
cular sprouting was determined by counting the number
of complete branches per branching point.
Animal model studies
As soon as tumors were confirmed by abdominal palpa-
tion, MYCN homozygous transgenic mice [18], were ran-
domized to four groups (n = 5/group) and injected
intraperitoneally daily for 7 days with control, TSA at 20
mg/kg of body weight, mouse IFNα at 1 × 106 IU/kg body
weight, or TSA and IFNα. Mice were sacrificed at the end
of the week of treatment. Tumors were then removed, for-
malin-fixed and paraffin-embedded. All studies involving
animals were approved by the animal care and ethics
committee of the University of New South Wales, Sydney,
Australia.
Immunohistochemical studies
Mouse tissue sections were incubated with goat anti-plate-
let endothelial cell adhesion molecule 1 (PECAM-1) anti-
body (1:500) (Santa Cruz Biotechnology), followed by
incubation with biotinylated rabbit, anti-goat antibody
(1:500) and streptavidin-horseradish peroxidase.
Endothelial cells were visualised with 3,3'-diaminobenzi-
dine solution, and micro-vessels were quantified as
described previously [29].
Statistical analyses
All data for statistical analyses were presented as mean
±standard error. Differences were analyzed for signifi-
cance using ANOVA among groups. A probability value of
0.05 or less was considered significant.
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